A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
← catalyst calendarNCT07076121 · readout in 988 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 2/3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
470estimated
Sites
269
Countries
Argentina, Australia, Austria +33
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-23 | actual | When the study began enrolling |
| Primary completion | 2029-05-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-03 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pancreatic Ductal Adenocarcinoma
Interventions
- Drug: Navlimetostat — also filed as BMS-986504, MRTX1719
- Drug: Gemcitabine
- Drug: Nab-paclitaxel — also filed as Abraxane
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFProgression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1)
measured Up to 3 years after last participant is randomized
Overall Survival (OS)
measured Up to 3 years after last participant is randomized
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed